Malcolm Ethridge from Capital Area Planning Group sees potential in ServiceNow, Inc. despite recent dip. Bristol-Myers and ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

The Cleveland Clinic's Nathan Pennell, M.D., Ph.D., is switching to the Big Pharma realm to head up hematology and oncology ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks. Read why BMY stock is a buy.

Bristol-Myers Squibb’s second quarter saw flat overall sales, but the company surpassed Wall Street expectations for both ...

The FDA has granted Breakthrough Therapy Designation to Bristol Myers Squibb (BMY) and SystImmune’s experimental drug iza-bren for treating advanced EGFR-mutant lung cancer after prior therapies fail, ...

Bristol Myers Squibb (NYSE: BMY) is a big name in healthcare. And over the years, it has always found ways to grow and expand its business. But this hasn't been a good buy of late. It's not just ...

Bristol Myers Squibb stock tanked in April after management lowered the midpoint of its earnings outlook for 2024 from $7.25 per share to just $0.55 to account for a $12.1 billion IPRD charge ...

Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The medication introduces a new approach by targeting M1 and M4 receptors ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.